About Wegovy (semaglutide injection) 1 Health Canada approved Wegovy in 2021 as a once-weekly treatment for Canadians living with obesity, supported by the efficacy and safety data from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program
For this reason, semaglutide isnt advised for people with a personal or family history of Multiple Endocrine Neoplasia syndrome type 2B, which is a rare disorder of the endocrine system
Thus, it serves as more than a weight loss toolits a comprehensive approach to health improvement
The SCALE trial measured outcomes at week 56, showing the 8% average body weight reduction
Boost Your Energy : Say goodbye to fatigue and power through your day with enhanced stamina and vitality
Metabolic Support: Beyond weight loss, the compound is being evaluated for its ability to regulate blood sugar and improve overall metabolic markers